👖 What should I know before starting GLP-1?

Before starting GLP-1 receptor agonists, it is important to understand that while these medications can provide significant weight loss and metabolic benefits, real-world effectiveness depends partly on adherence, dosing, and continued treatment, gastrointestinal side effects are common and often lead to discontinuation, and long-term success requires ongoing lifestyle changes and monitoring.

GLP-1 receptor agonists can lead to substantial weight loss, but real-world results are often less dramatic than clinical trials due to lower adherence and dosing. In clinical trials, weight loss with semaglutide ranges from 15% to 20% of body weight, but real-world outcomes tend to be considerably lower.

Gastrointestinal side effects like nausea, vomiting, and digestive discomfort are among the most common adverse events and a major reason some people stop GLP-1 therapy. Discontinuation rates in real-world settings can reach 20% to 50% within the first year, due to factors such as side effects, cost, access, insurance coverage, and supply issues.

GLP-1 receptor agonists were first approved for type 2 diabetes in 2005 and have rapidly expanded in use for obesity management. The popularity of GLP-1 medications has led to shortages and increased public discussion about their role in weight loss culture. GLP-1 drugs have influenced the cultural conversation about obesity, shifting perceptions toward medical management and away from solely lifestyle-based approaches.

Eat smaller, low-fat meals to help minimize nausea when starting GLP-1 medications. Stay hydrated and avoid high-sugar or high-fat foods, which can worsen gastrointestinal side effects. Plan meals and snacks in advance, as appetite suppression may lead to skipping meals and missing essential nutrients.